2/22/2018
`
`Apotex
`
`Sign up for the PharmacyTimes Newsletter
`
`Clinical
`Resources
`
`Videos
`
`Publications
`
`Contributors
`
`SHOWING CONTENT FOR:
`Community Pharmacist ▼
`Conference
`Continuing
`Coverage
`Education
`
` Search
`
` Login
`
`Back to issue
`Apotex
`
`AUGUST 24, 2016
`
`We want to know your top recommended
`OTC products!
`
`Pharmacy Times® and U.S. News would like to hear
`what OTC products you most often recommend. You will
`have the chance to win an iPhone X!
`
`Pharmacist Education
`
`Clinical features with downloadable PDFs
`
`Apotex Corp., headquartered in Weston, Florida, is the U.S. affiliate of Apotex Inc., the 7th largest
`generic pharmaceutical company in the world. Apotex employs over 10,000 people and can produce
`up to 24 billion dosages a year across a full range of dosage forms, including tablets, capsules, oral
`suspensions, ophthalmic, nasals and liquid products. These products are sold into more than 120
`countries around the world. A strong pipeline of over 300 more products in development is the key to
`keeping this strong market presence.
`
`Frequently recognized for superior service by customers, Apotex Corp. is ranked in the top ten U.S.
`generic pharmaceutical manufacturers by sales and is 10th in total generic prescriptions, according to
`recent IMS HEALTH data. Apotex’s expansive product portfolio spans a wide range of therapeutic
`classes, including cardiovascular, antiinfectives, gastrointestinal, central nervous system, mental
`health, pain management and respiratory. The company continues to diversify its product mix by
`adding new therapeutic areas and dosage forms such as transdermal patches and injectables.
`Recently, Apotex launched the first generic version of Merck’s Nasonex® nasal spray (mometasone
`furoate monohydrate) in the United States.
`
`“We are very pleased to make a more affordable version of this important allergy medicine available to
`the U.S. public. Apotex is dedicated to bringing high quality versions of complex generic products to
`market, and we are delighted that these efforts will generate substantial savings for the U.S.
`healthcare system.” said Apotex Chief Executive Officer and President, Dr. Jeremy B. Desai.
`
`Apotex has long been known for building strong industry partnerships to champion the cause of
`making affordable medicines and driving down healthcare costs. One such partnership is with the
`Generic Pharmaceutical Association (GPhA). In February of this year, Jeff Watson, President, Global
`Generics was appointed to the 2016 GPhA Board of Directors. “This industry continues to be the most
`reliable source of savings in the health sector,” said Watson. “I look forward to working with the
`association leadership to advance the mission of GPhA and its member companies, improving the
`lives of millions of patients while enhancing timely access to quality, affordable medicines.”
`
`A Forward-Thinking Approach
`
`Apotex is passionate in its approach to research and development. The company will spend $2 billion
`in the next ten years on R&D, with a significant portion of those resources focused on the company’s
`emerging biosimilar program. Apotex currently has two biosimilar applications (filgrastim [Neupogen®]
`and pegfilgrastim [Neulasta®]) under active review with the FDA. “We are very pleased to be at the
`forefront of companies who will introduce high quality biosimilar products into the U.S. marketplace,”
`said Dr. Desai. “Our entry into this new frontier of medicine is a watershed event in Apotex’s 42-year
`history of providing quality, affordable medicines to patients in need around the globe.”
`
`Reliable Advocate and Trusted Partner
`http://www.pharmacytimes.com/publications/supplement/2016/generic-supplement-2016/apotex-advancing-generics
`
`Exhibit 1131
`IPR2017-00807
`1/3
`ARGENTUM
`
`000001
`
`
`
`Apotex
`
`Sign up for the PharmacyTimes Newsletter
`
`Clinical
`Resources
`
`Videos
`
`Publications
`
`Contributors
`
`SHOWING CONTENT FOR:
`Community Pharmacist ▼
`Conference
`Continuing
`Coverage
`Education
`
` Search
`
` Login
`
`Back to issue
`Apotex
`
`AUGUST 24, 2016
`
`We want to know your top recommended
`OTC products!
`
`Pharmacy Times® and U.S. News would like to hear
`what OTC products you most often recommend. You will
`have the chance to win an iPhone X!
`
`Pharmacist Education
`
`Clinical features with downloadable PDFs
`
`Apotex Corp., headquartered in Weston, Florida, is the U.S. affiliate of Apotex Inc., the 7th largest
`generic pharmaceutical company in the world. Apotex employs over 10,000 people and can produce
`up to 24 billion dosages a year across a full range of dosage forms, including tablets, capsules, oral
`suspensions, ophthalmic, nasals and liquid products. These products are sold into more than 120
`countries around the world. A strong pipeline of over 300 more products in development is the key to
`keeping this strong market presence.
`
`Frequently recognized for superior service by customers, Apotex Corp. is ranked in the top ten U.S.
`generic pharmaceutical manufacturers by sales and is 10th in total generic prescriptions, according to
`recent IMS HEALTH data. Apotex’s expansive product portfolio spans a wide range of therapeutic
`classes, including cardiovascular, antiinfectives, gastrointestinal, central nervous system, mental
`health, pain management and respiratory. The company continues to diversify its product mix by
`adding new therapeutic areas and dosage forms such as transdermal patches and injectables.
`Recently, Apotex launched the first generic version of Merck’s Nasonex® nasal spray (mometasone
`furoate monohydrate) in the United States.
`
`“We are very pleased to make a more affordable version of this important allergy medicine available to
`the U.S. public. Apotex is dedicated to bringing high quality versions of complex generic products to
`market, and we are delighted that these efforts will generate substantial savings for the U.S.
`healthcare system.” said Apotex Chief Executive Officer and President, Dr. Jeremy B. Desai.
`
`Apotex has long been known for building strong industry partnerships to champion the cause of
`making affordable medicines and driving down healthcare costs. One such partnership is with the
`Generic Pharmaceutical Association (GPhA). In February of this year, Jeff Watson, President, Global
`Generics was appointed to the 2016 GPhA Board of Directors. “This industry continues to be the most
`reliable source of savings in the health sector,” said Watson. “I look forward to working with the
`association leadership to advance the mission of GPhA and its member companies, improving the
`lives of millions of patients while enhancing timely access to quality, affordable medicines.”
`
`A Forward-Thinking Approach
`
`Apotex is passionate in its approach to research and development. The company will spend $2 billion
`in the next ten years on R&D, with a significant portion of those resources focused on the company’s
`emerging biosimilar program. Apotex currently has two biosimilar applications (filgrastim [Neupogen®]
`and pegfilgrastim [Neulasta®]) under active review with the FDA. “We are very pleased to be at the
`forefront of companies who will introduce high quality biosimilar products into the U.S. marketplace,”
`said Dr. Desai. “Our entry into this new frontier of medicine is a watershed event in Apotex’s 42-year
`history of providing quality, affordable medicines to patients in need around the globe.”
`
`Reliable Advocate and Trusted Partner
`http://www.pharmacytimes.com/publications/supplement/2016/generic-supplement-2016/apotex-advancing-generics
`
`Exhibit 1131
`IPR2017-00807
`1/3
`ARGENTUM
`
`000001
`
`
`
`Apotex
`2/22/2018
`Apotex believes all manufacturers have a corporate citizenship responsibility to the global community.
`The company carries out this responsibility through various national initiatives and partnerships and
`continues to donate life-saving medicines to developing countries to alleviate human suffering and
`save the lives of many people around the world. Apotex is committed to serving patients by advancing
`generics and providing high quality, affordable products.
`
`
`For more information, visit www.apotexcorp.com.
`
` SHARE THIS
`
`◄
`
`0
`
` RELATED COVERAGE
`
`FDA Approves Generic Drug
`for Relapsing Multiple
`Sclerosis
`
`Generic Product News
`(January 2018)
`
`Clinical Use of Generic
`Injectable Drugs in
`Hospitalized Patients
`
` YOU MAY ALSO BE INTERESTED IN
`
`Top 200 Drugs of 2010
`
`SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
`Personalize the information you receive by selecting targeted content and special offers.
`
`Enter your email address
`
`Sign Up
`
`RELATED SITES
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`About Pharmacy Times
`Pharmacy Times® is the #1 full-service pharmacy media resource in the
`industry. Founded in 1897, Pharmacy Times® reaches a network of over
`1.3 million retail pharmacists. Through our print, digital and live events
`channels, Pharmacy Times® provides clinically based, practical and timely
`information for the practicing pharmacist. Features and specialized
`departments cover medication errors, drug interactions, patient education,
`pharmacy technology, disease state management, patient counseling,
`product news, pharmacy law and health-system pharmacy. Pharmacy
`Times Continuing Education™ (PTCE) is accredited by the Accreditation
`Council for Pharmacy Education (ACPE) as a provider of continuing
`pharmacy education.
`
`
`
`Pharmacy & Healthcare Communications, LLC
`
`2 Clarke Drive
`
`Suite 100
`
`Cranbury, NJ 08512
`P: 609-716-7777
`
`F: 609-716-9038
`
`
`http://www.pharmacytimes.com/publications/supplement/2016/generic-supplement-2016/apotex-advancing-generics
`
`2/3
`
`000002
`
`
`
`2/22/2018
`
`
`Apotex
`
`Careers Contact Us Feedback Advertise With Us Terms & Conditions Privacy Press Room Conference Coverage
`
`Copyright © 2006-2017 Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
`
`http://www.pharmacytimes.com/publications/supplement/2016/generic-supplement-2016/apotex-advancing-generics
`
`3/3
`
`000003
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
